A METHOD OF STATISTICAL-ANALYSIS OF THE AMDP PSYCHOPATHOLOGY RATING-SCALE BASED ON THE RESULTS OF A 2 YEAR STUDY OF 2 LONG-ACTING NEUROLEPTICS IN CHRONIC-SCHIZOPHRENICS

被引：0
|
作者：
SUSSMAN, PS [1 ]
LAPIERRE, YD [1 ]
机构：
[1] UNIV OTTAWA,ROYAL OTTAWA HOSP,DEPT PSYCHIAT,OTTAWA K1N 6N5,ONTARIO,CANADA
来源：
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1980年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：239 / 239
页数：1
相关论文
共 9 条
  • [1] STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC-SCHIZOPHRENICS - 18-MONTH OPEN MULTICENTRIC STUDY
    SIMON, P
    FERMANIAN, J
    GINESTET, D
    GOUJET, MA
    PERONMAGNAN, P
    ARCHIVES OF GENERAL PSYCHIATRY, 1978, 35 (07) : 893 - 897
  • [2] Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study
    Cervin, Anders
    Rimmer, Joanne
    Wrobel, Agnieszka
    Abelak, Yogen
    Brayton, Lindsay
    Kuang, Yina
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (02) : 147 - 159
  • [3] Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study
    Pietrini, Francesco
    Tatini, Lorenzo
    Santarelli, Gabriele
    Brugnolo, Dario
    Squillace, Marco
    Bozza, Bernardo
    Ballerini, Andrea
    Ricca, Valdo
    D'Anna, Giulio
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2021, 25 (03) : 307 - 315
  • [4] One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study
    Kirchmayer, Ursula
    Cascini, Silvia
    Agabiti, Nera
    Di Martino, Mirko
    Bauleo, Lisa
    Formoso, Giulio
    Voci, Claudio
    Pistelli, Riccardo
    Patorno, Elisabetta
    Davoli, Marina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (05) : 578 - 589
  • [5] Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up
    Kimura, Hiroshi
    Kanahara, Nobuhisa
    Sasaki, Tsuyoshi
    Komatsu, Naoya
    Ishige, Minoru
    Muneoka, Katsumasa
    Ino, Hidetoshi
    Yoshimura, Kazuyuki
    Yamanaka, Hiroshi
    Suzuki, Tomotaka
    Komatsu, Hideki
    Watanabe, Hiroyuki
    Shimizu, Eiji
    Iyo, Masaomi
    JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (08) : 795 - 802
  • [6] Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
    Smith, Graham H. R.
    Henry, W. Keith
    Podzamczer, Daniel
    Del Mar Masia, Maria
    Bettacchi, Christopher J.
    Arasteh, Keikawus
    Jaeger, Hans
    Khuong-Josses, Marie-Aude
    Luisa Montes-Ramirez, Maria
    Stellbrink, Hans-Jurgen
    Yazdanpanah, Yazdan
    Richmond, Gary J.
    Sutton, Kenneth C.
    Zhang, Feifan
    McCoig, Cynthia C.
    St Clair, Marty H.
    Vandermeulen, Kati
    Van Solingen-Ristea, Rodica
    Smith, Kimberly Y.
    Margolis, David A.
    Spreen, William R.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (09):
  • [7] Long-Term Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease Treated with Twice-Daily Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: Results from the TORCH Study
    Naya, I.
    Driessen, M. T.
    Paly, V.
    Gunsoy, N.
    Risebrough, N.
    Briggs, A.
    Ismaila, A. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [8] Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data
    Yang, Chun-Ting
    Yao, Wen-Yu
    Ou, Huang-Tz
    Kuo, Shihchen
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 198
  • [9] Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
    Landovitz, Raphael J.
    Hanscom, Brett S.
    Clement, Meredith E.
    Tran, Ha, V
    Kallas, Esper G.
    Magnus, Manya
    Sued, Omar
    Sanchez, Jorge
    Scott, Hyman
    Eron, Joe J.
    del Rio, Carlos
    Fields, Sheldon D.
    Marzinke, Mark A.
    Eshleman, Susan H.
    Donnell, Deborah
    Spinelli, Matthew A.
    Kofron, Ryan M.
    Berman, Richard
    Piwowar-Manning, Estelle M.
    Richardson, Paul A.
    Sullivan, Philip A.
    Lucas, Jonathan P.
    Anderson, Peter L.
    Hendrix, Craig W.
    Adeyeye, Adeola
    Rooney, James F.
    Rinehart, Alex R.
    Cohen, Myron S.
    Mccauley, Marybeth
    Grinsztejn, Beatriz
    LANCET HIV, 2023, 10 (12): : E767 - E778
1